Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭

doi:10.16352/j.issn.1001-6325.2022.09.1350

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (9): 1350-1354.doi: 10.16352/j.issn.1001-6325.2022.09.1350

Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭

张晓雷^1*, 刘静², 李朝萍³

1. 黄河三门峡医院乳腺外科, 河南三门峡 472000;
2. 黄河三门峡医院健康体检科, 河南三门峡 472000;
3. 郑州大学附属洛阳中心医院肿瘤中心, 河南洛阳 471000

收稿日期:2021-06-11 修回日期:2021-12-13 出版日期:2022-09-05 发布日期:2022-09-02
通讯作者: zhangxl202106@126.com
基金资助:
河南省科技发展计划(1603002A-1)

Circ_0032821 is involved in sorafenib's inhibition of the proliferation, migration and invasion of breast cancer cell line T47D

ZHANG Xiao-lei^1*, LIU Jing², LI Chao-ping³

1. Department of Breast Surgery, Sanmenxia Hospital of Yellow River, Sanmenxia 472000;
2. Department of Health Examination, Sanmenxia Hospital of Yellow River, Sanmenxia 472000;
3. Department of Cancer Center, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471000, China

Received:2021-06-11 Revised:2021-12-13 Online:2022-09-05 Published:2022-09-02

摘要/Abstract

摘要： 目的探讨索拉非尼对乳腺癌细胞系T47D增殖、迁移、侵袭的影响和可能的作用机制。方法通过CCK-8法、平板集落实验、划痕愈合实验和Transwell小室法检测索拉非尼(2.5、5和10 μmol/L)对T47D细胞增殖、集落形成、迁移和侵袭的影响。RT-qPCR检测circ_0032821表达。将circ_0032821小干扰RNA(si-circ_0032821)、circ_0032821过表达质粒分别转染T47D细胞,检测干扰circ_0032821或过表达circ_0032821联合索拉非尼对T47D细胞恶性行为的影响。结果索拉非尼处理后,T47D细胞增殖抑制率显著升高(P＜0.05),集落形成数、划痕愈合率、侵袭数以及circ_0032821表达显著降低(P＜0.05)。沉默circ_0032821后,T47D细胞增殖抑制率显著升高(P＜0.05),集落形成数、划痕愈合率、侵袭数显著降低(P＜0.05)。过表达circ_0032821明显减弱索拉非尼对T47D细胞增殖、迁移、集落形成和侵袭的影响。结论索拉非尼可抑制T47D细胞增殖、迁移和侵袭,其机制可能与下调circ_0032821表达有关。

关键词: 索拉非尼, 乳腺癌, 增殖, 迁移, circ_0032821

Abstract: Objective To investigate the effect and possible mechanism of sorafenib on the proliferation, migration and invasion of breast cancer cell line T47D. Methods Effects of sorafenib (2.5, 5 and 10 μmol/L) on T47D cells proliferation, colony formation, migration and invasion were detected by CCK-8 experiment, plate cloning experiment, scratch healing experiment and Transwell experiment. RT-qPCR was applied to detect circ_0032821 expression. The circ_0032821 small interfering RNA(si-circ_0032821) and circ_0032821 over-expression plasmid were transfected into T47D cells respectively. And the effect of interference with circ_0032821 or circ_0032821 over-expression combined with sorafenib on the malignant behavior of T47D cells was detected. Results The cell proliferation inhibition rate T47D cells were significantly increased after sorafenib treatment (P＜0.05); The colony formation number, scratch healing rate, invasion number, and circ_0032821 expression were significantly decreased(P＜0.05).After silencing with the expression of circ_0032821, the proliferation inhibition rate of T47D cells was significantly increased (P＜0.05); The colony formation number, scratch healing rate and invasion number were significantly reduced(P＜0.05). Circ_0032821 over-expression significantly reduced the effects of sorafenib on the proliferation, migration colony formation and invasion of T47D cells (P＜0.05). Conclusions Sorafenib can inhibit T47D cell proliferation, migration and invasion. And the mechanism may be explained by the down-regulation of circ_0032821.

Key words: sorafenib, breast cancer, proliferation, migration, circ_0032821

中图分类号:

R737.9

张晓雷, 刘静, 李朝萍. Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(9): 1350-1354.

ZHANG Xiao-lei, LIU Jing, LI Chao-ping. Circ_0032821 is involved in sorafenib's inhibition of the proliferation, migration and invasion of breast cancer cell line T47D[J]. Basic & Clinical Medicine, 2022, 42(9): 1350-1354.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2022.09.1350

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2022/V42/I9/1350

参考文献 14

[1]	Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Sorafenib[J]. Profiles Drug Subst Excip Relat Methodol, 2019, 44: 239-266.
[2]	Zanotto-Filho A, Rajamanickam S, Loranc E, et al. Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells[J]. Cancer Lett, 2018, 425: 101-115.
[3]	Sang Y, Chen B, Song X, et al. CircRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer[J]. Mol Ther, 2019, 27: 1638-1652.
[4]	Liu Z, Zhou Y, Liang G, et al. Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p[J]. Cell Death Dis, 2019, 10: 55-65.
[5]	Jiang Y, Zhang Y, Chu F, et al. Circ_0032821 acts as an oncogene in cell proliferation, metastasis and autophagy in human gastric cancer cells in vitro and in vivo through activating MEK1/ERK1/2 signaling pathway[J]. Cancer Cell Int, 2020, 20: 74-84.
[6]	孙时华, 严富华, 姜建军, 等. 索拉非尼对肾癌786-O细胞株体外培养的增殖抑制作用[J].浙江医学, 2010, 32: 517-518, 599.
[7]	程秀莲, 韩利峰, 唐秀丽, 等. 索拉非尼对肝癌细胞增殖凋亡及JAK-STAT信号通路的影响[J]. 肝脏, 2020, 25: 49-52.
[8]	Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66: 11851-11858.
[9]	张新然, 张弋, 高慧儿, 等. Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药[J].基础医学与临床, 2020, 40: 473-478.
[10]	陈怡, 陈烁, 郑娟红, 等. 索拉非尼对胃癌细胞MGC80-3抑制作用实验研究[J]. 中国现代医生, 2015, 21: 8-10.
[11]	周雪, 王娟, 马淑梅, 等. 索拉非尼联合多柔比星对人乳腺癌MDA-MB-231细胞和人肺癌A549细胞抑制作用的研究[J]. 世界临床药物, 2014, 35: 101-105.
[12]	Dattachoudhury S, Sharma R, Kumar A, et al. Sorafenib inhibits proliferation, migration and invasion of breast cancer cells[J]. Oncology, 2020, 98: 478-486.
[13]	Chen L, Chi K, Xiang H, et al. Circ_0032821 facilitates gastric cancer cell proliferation, migration, invasion and glycolysis by regulating miR-1236-3p/HMGB1 axis[J]. Cancer Manag Res, 2020, 12: 9965-9976.
[14]	Zhong Y, Wang D, Ding Y, et al. Circular RNA circ_0032821 contributes to oxaliplatin (OXA) resistance of gastric cancer cells by regulating SOX9 via miR-515-5p[J]. Biotechnol Lett, 2021, 43: 339-351.

[1]	贺晶, 李艳, 王延峰, 鲍慧. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42(9): 1356-1361.
[2]	钟金鹏, 杨莉, 王辉波, 陈红健, 李金伟, 文明洪, 吕云波. HMGB1减弱丹参酮ⅡA对大鼠心肌缺血/再灌注损伤的缓解作用[J]. 基础医学与临床, 2022, 42(9): 1333-1338.
[3]	王娟, 张晓燕, 朱爱华, 于宏波, 范新丹, 汤春辉, 姚秀芳. Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关[J]. 基础医学与临床, 2022, 42(9): 1391-1399.
[4]	沈永华, 汪峻峰, 程泽星, 冯娟娟. 秦皮甲素抑制人鼻咽癌细胞系HNE-3增殖[J]. 基础医学与临床, 2022, 42(8): 1237-1242.
[5]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.
[6]	江宁, 郭钧, 刘铖, 周举. 莪术醇抑制人骨肉瘤细胞系的增殖和促凋亡[J]. 基础医学与临床, 2022, 42(8): 1200-1205.
[7]	刘磊, 李世宝, 张好良. 沉默lnc-SLC2A12-10:1抑制人胃癌细胞系AGS增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(7): 1071-1076.
[8]	钟鸣, 于修义, 郭伟溪, 方正. 麦冬皂苷B抑制人食管鳞状细胞癌细胞系EC9706增殖和迁移[J]. 基础医学与临床, 2022, 42(7): 1053-1059.
[9]	王子辕, 段昭君, 罗云萍. 小鼠乳腺癌肺特异性转移细胞亚系的建立和验证[J]. 基础医学与临床, 2022, 42(7): 1083-1091.
[10]	韩雪莹, 崔丰, 李隽. 乳腺癌缺失因子1(DBC1)影响乳腺癌细胞系对依托泊苷的敏感性[J]. 基础医学与临床, 2022, 42(7): 1060-1066.
[11]	康有力, 赵丹, 杜文静, 李莉. SIRT5通过调控ALDH5A1的琥珀酰化促进人乳腺癌细胞的增殖[J]. 基础医学与临床, 2022, 42(7): 1099-1107.
[12]	白冰, 张海芳, 杨庆良, 秦悦, 周晨龙, 宋歌, 王颖. 下调lncRNA RHPN1-AS1抑制人膀胱癌细胞系T24增殖和迁移[J]. 基础医学与临床, 2022, 42(6): 940-944.
[13]	谢利华, 杨奇, 李雅倩, 谢心悦, 雷诗娟, 周琳. 转录因子Kaiso下调人乳腺癌细胞系中lncRNA MEG3的表达[J]. 基础医学与临床, 2022, 42(5): 758-762.
[14]	杜雪梅, 张运梅, 周文婷, 吕宏. miR-655-3p靶向KIF20A抑制人肺腺癌细胞系A549迁移及侵袭[J]. 基础医学与临床, 2022, 42(4): 599-606.
[15]	孙全鹏, 樊超, 展德玺, 范怡明, 孙伟峰. 罗哌卡因抑制人肝癌细胞系Hep3B增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(3): 448-453.

Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭

Circ_0032821 is involved in sorafenib's inhibition of the proliferation, migration and invasion of breast cancer cell line T47D

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 14

相关文章 15

编辑推荐

Metrics

本文评价